

A

A&E CONNOCK
in *Company Profiles*, 1

ABEL S.
Preparative scale chiral chromatography – 5, 9

ACHILLEOS E. C.
Risk and variability analysis in the batch manufacturing of active pharmaceutical ingredients and specialty chemicals – 1-2, 14

ACROS ORGANICS
in *Company Profiles*, 2

ARCHIMICA
Steady. Strong. Focused on pharmaceuticals – Interview to R. PFIRMANN – 10, 34

B

BASA L.
Detecting and quantitating a peptide biomarker for hypertension in plasma – Research report – 4, 6

BASF
Orgamol, the Swiss fine chemical company, is now part of BASF, the world's leading chemical company – in *Company Profiles*, 3

BAUMEISTER H.
A novel human expression system for production of higher active biotherapeutics with optimised glycosylation – 4, 21

BENIS M.
New research vision is springboard for business success – 7-8, 6

BIELER N.
Microreactor technology and continuous processes in the fine chemical and pharmaceutical industries – 6, 14

BRANDT O.
A new peptide array format for the analysis of epitopes, binding partners and the characterization of antibodies – 7-8, 10

C

CALANDRANIS J.
Risk and variability analysis in the batch manufacturing of active pharmaceutical ingredients and specialty chemicals – 1-2, 14

CARGOLUX AIRLINES Intl.
Pharmaceuticals o/b Cargolux Aircraft – 6, 6
World class in air cargo – 9, 14

CHILTERN
Chiltern's Integrated Resourcing Division eyes India – 7-8, 40

CHRUSCINSKI L.
Spectroscopic studies of Cu (II) complexes with an insect kinin analog – 4, 10

CLARIANT LSM (DEUTSCHLAND) GmbH
Clariant positioned to take advantage of upswing in outsourcing in the pharmaceutical industry – 1-2, 6

COGNIS
Get to know Cognis' world of natural

choices – in *Company Profiles*, 4

COLDER PRODUCTS Co.
Integrating RFID technology can create smarter manufacturing operations – 9, 38
Stainless steel to disposable: Creating a connection – Interview to J. BOEHM – 10, 51

CRICHTON R. R.
Metal-based neurodegeneration – 1-2, 37

D

D&O PHARMACHEM Inc.
in *Company Profiles*, 5

DAMANI M.
Re-engineering the pharmaceutical company: Outsourcing and the emergence of the virtual company – 11-12, 17

DSM FINE CHEMICALS
Fine chemicals for fine applications – in *Company Profiles*, 6

DSM NUTRITIONAL PRODUCTS
Unlimited innovation – in *Company Profiles*, 7

E

EACHUS A. C.
Major issues for the pharmaceutical industry in 2006 – 5, 13

ELSMORE R.
Biocides 2005 – A global perspective – 3, 30

EUROPEAN FINE CHEMICALS GROUP
EFCG announces action plans to improve competitiveness of EU fine chemical producers – 1-2, 40

F

F.I.S. – FABBRICA ITALIANA SINTETICI SpA
A resource for results – Interview to R. LAFORCE – 11-12, 26

Technology, production, experience: The powerbeat for APIs – in *Company Profiles*, 8

FLAVEX NATUREXTRAKTE GmbH
Natural skin care and wellness... with CO₂ extracts – in *Company Profiles*, 9

FLINN T.
Setting new drug specifications – An outsourcing API supplier's perspective – 3, 44

FMC LITHIUM
in *Company Profiles*, 5; 10; 11

FROST & SULLIVAN
Pharmaceutical and biotechnology companies adopt outsourcing practices to combat rising costs – 1-2, 10
European medical device companies face increasing competition from low-cost devices manufactured in Asia – 3, 34

Growing healthcare costs and the rise in pharmaceutical expenditure component prompt cost-containment initiatives by various European governments – 3, 34
Genomics and proteomics sequencing as well as characterisation of expressed

human genes create new opportunities in the Asia Pacific drug discovery market – 3, 35

Innovative technologies to promote enhanced productivity across the European drug discovery market – 4, 30

Surge in strategic alliances and licensing deals to boost productivity of pharmaceutical companies – 5, 19
Neurological disorders and high level of unmet clinical need to create opportunities in European central nervous system therapeutics market – 6, 34

Rising need for purity spurs growth in the European nucleic acid isolation market – 7-8, 46

European antidepressants markets – 9, 26

Nanotechnology holds promise of revolutionising European drug discovery markets – 9, 26

Advantages of greater speed and accuracy to promote adoption of smart card applications by healthcare sector – 10, 54

Affordable, innovative and effective product solutions to spur European diabetes market – 10, 54

Emergence of new technologies and application areas to sustain growth in the European IVD markets – 11-12, 22

Instrument innovations promote growth in the European immunodiagnostics automation markets – 11-12, 22

Europe's ageing population presents tremendous growth potential for Alzheimer's disease therapeutics markets – 11-12, 23

Technological advancements transforming the European neurological monitoring market – 11-12, 23

Despite technical hurdles, potential to transform drug discovery and development to drive gene expression markets – 11-12, 24

G

GARBAY C.
Peptides as antagonists of the VEGF receptors – 4, 15

GAUSEPOHL H.
A new peptide array format for the analysis of epitopes, binding partners and the characterization of antibodies – 7-8, 10

GAUTIER B.
Peptides as antagonists of the VEGF receptors – 4, 15

GEE LAWSON
in *Company Profiles*, 8

GHARPURE Y. H.
The Indian specialty chemical industry – 7-8, 36

GONCALVES V.
Peptides as antagonists of the VEGF receptors – 4, 15

GREENE C.
India and China - Building a generic presence in Western markets – 9, 19

GRIFFITHS M. C.
Profiling activities and risks in producing highly potent development APIs – 1-2, 20

GROUPE SNPE
ISOHEM: Building the molecules of life – in *Company Profiles*, 24

H -----

HALOCARBON PRODUCTS Corp
Routes to sevoflurane – 1-2, 26

HAMMOND M.
Business without frontiers – Pragmatic approaches to improving communication with clients – 10, 8

HEITMANN A. C.
Lanxess - Our new approach to the chemical industry – 5, 20

HELSINN
Helsinn Chemical Operations – Interview to G. HAERING – 10, 28
Integrated manufacturing – in *Company Profiles*, 12

HOFFMANN-LA ROCHE
Drugs from the fermenter – 1-2, 32
Treatment begins with diagnosis – 3, 17

HU JIANMING
Synthesis and characterisation of new AB-PBO monomers and their application – 6, 30
Efficient synthesis and application of new AB-PBO monomers – 9, 30

HUNTER C.
Detecting and quantitating a peptide biomarker for hypertension in plasma – Research report – 4, 6

I -----

INDENA
Plants help fight cardiovascular disorders – 7-8, 30
Indena confirms world leadership in botanical derivatives – 7-8, 30
Indena and Nerviano Medical Sciences agree to scale up new high potency molecules – 9, 22
Mirtoselect® new logo campaign – 9, 22
HPLC: Adulterated products exposed – New studies demonstrate Mirtoselect® qualities – 11-12, 38
Stack the odds – in *Company Profiles*, 13

INGUIMBERT N.
Peptides as antagonists of the VEGF receptors – 4, 15

INSTITUT ROSELL LALLEMAND
in *Company Profiles*, 11

J -----

JAIRAJ V.
Metathesis - A Nobel Prize winning reaction – 4, 35
Biological applications of organofluorine compounds – 6, 24

JIN NINGREN
Synthesis and characterisation of new AB-PBO monomers and their application – 6, 30
Efficient synthesis and application of new AB-PBO monomers – 9, 30

K -----

KACZMAREK K.

Spectroscopic studies of Cu (II) complexes with an insect kinin analog – 4, 10

KAMBOURAKIS S.
Ketoreductases: General stereoselective catalysts for the facile synthesis of a broad range of chiral alcohols – 9, 2

KELLE R.
On the way to the GLASS CELL – Degussa starts joint project for systems biology research on *Corynebacterium* – 10, 18

KERMANI F.
A perspective on Canada – 3, 23
Japanese pharma considers Eastern promise – 4, 2
Employment dynamics in the European pharmaceutical industry – 5, 2
China: A market of challenges and opportunities – 6, 2

Can Latin America lead the way? – 9, 16
Analysing Australia's pharmaceutical future – 10, 4

KIRR C.
cOmplete lysis kits: Rapid protein extraction and simultaneous protection against proteases – 9, 24

KIRSCH PHARMA
Kirsch Pharma South Africa (Pty) Ltd. – in *Company Profiles*, 14

KLEIN J.
About concrete, stainless steel and microbes – 3, 6

KNIGHT D. J.
Preparing for REACH: The new registration, evaluation and authorisation scheme for chemicals in EU – 6, 42

KOUL V. K.
Metathesis - A Nobel Prize winning reaction – 4, 35
Biological applications of organofluorine compounds – 6, 24

KURUNDKAR S.
Oral systemic enzyme therapy: Answer for safe and cost effective cardiovascular health – 7-8, 42

L -----

LANXESS
in *Company Profiles*, 15

LAWRENCE S. A.
Carbon-carbon coupling reactions with alkynes – 6, 19

LENOIR C.
Peptides as antagonists of the VEGF receptors – 4, 15

LIPID NUTRITION
Clarinol – For people who are active about weight management – in *Company Profiles*, 16

LIU XIAOFENG
Synthesis and characterisation of new AB-PBO monomers and their application – 6, 30

LODYGA-CHRUSCINSKA E.
Spectroscopic studies of Cu (II) complexes with an insect kinin analog – 4, 10

LONDESBROUGH D.
Setting new drug specifications – An outsourcing API supplier's perspective – 3, 44

LOSSEV M. V.
The prospects of synthetic antigens in diagnostics and vaccinal prevention of highly genetically variable infectious agents – 11-12, 6

M -----

MALLIKARJUNA S. H.
Oral systemic enzyme therapy: Answer for safe and cost effective cardiovascular health – 7-8, 42

MALTA ENTERPRISE
Malta Enterprise at APIs Europe – 6, 10

MARAGNI P.
Selective N-demethylation reactions on erythromycin derivatives – 1-2, 28

MELOTTO E.
Selective N-demethylation reactions on erythromycin derivatives – 1-2, 28

MEYER H.-P.
About concrete, stainless steel and microbes – 3, 6

MICERA G.
Spectroscopic studies of Cu (II) complexes with an insect kinin analog – 4, 10

MICHIELETTO I.
Selective N-demethylation reactions on erythromycin derivatives – 1-2, 28

MORFLEX
Morflex is the global leader in citric acid esters – in *Company Profiles*, 17

MORRIS D. J.
Weighing is optional: Highly active and practical catalysts for asymmetric ketone transfer hydrogenation – 9, 8

MUELLER P. M.
Profiling activities and risks in producing highly potent development APIs – 1-2, 20

MUGHAN T.
Business without frontiers – Pragmatic approaches to improving communication with clients – 10, 8

N -----

NACHMAN R. J.
Spectroscopic studies of Cu (II) complexes with an insect kinin analog – 4, 10

NEMETZ C.
cOmplete lysis kits: Rapid protein extraction and simultaneous protection against proteases – 9, 24

O -----

OLDZIEJ S.
Spectroscopic studies of Cu (II) complexes with an insect kinin analog – 4, 10

OXON ITALIA S.p.A.
in *Company Profiles*, 17

OZA P.
Pharmaceutical project management: A need of the hour – 3, 27

P -----

PALKA C. L.

How small changes can make a big difference – 1-2, 2

PERLMUTTER B. A.

Thin-cake filtration technologies for removing activated carbon, catalysts and other trace solids from Active Pharmaceutical Ingredient (API) slurries – 3, 38

PETRIDES D. P.

Risk and variability analysis in the batch manufacturing of active pharmaceutical ingredients and specialty chemicals – 1-2, 14

PISTOLESI R.

The recent opinion of the Enlarged Board of Appeal seems to confirm the established case law – 3, 2
The clinical trials and the "experimental use exemption": The European scenario after the EU directive 2004/27/EC – 11-12, 2

PLASTIAPE

Metered Dose Inhalers (MDI) – 11-12, 36

Multi-monodose dry powder inhaler: A clear example of the designing ability that the company provides its customers with – in *Company Profiles*, 18

Collaboration with the University of Sydney: An important step in the understanding of the fluid dynamics of the inhalers – in *Company Profiles*, 19

R

RAJURKAR S.

Oral systemic enzyme therapy: Answer for safe and cost effective cardiovascular health – 7-8, 42

RAN NINGQING

Applications of biocatalysis in the development of green chemistry – 9, 34

REANAL FINECHEMICAL Co.

in *Company Profiles*, inside back cover

RECORDATI

Recordati - A European specialty pharmaceutical group – Interview to G. OBERRAUCH – 11-12, 32

RESELLI A.

Selective N-demethylation reactions on erythromycin derivatives – 1-2, 28

RISBUD S.

Oral systemic enzyme therapy: Answer for safe and cost effective cardiovascular health – 7-8, 42

ROBERGE D. M.

Microreactor technology and continuous processes in the fine chemical and pharmaceutical industries – 6, 14

ROCHE APPLIED SCIENCE

PCR: Shifting from research to medicine – Interview to M. BAIER – 10, 46

ROCHE DIAGNOSTICS

Ultrafast sequencing boosts target identification in diarylquinoline drug research – 4, 33

International Census of Marine Microbes reveals a greater level of marine diversity using ultrafast sequencing system from Roche Diagnostics – 11-12, 14

Powered by Genome Sequencer 20 from Roche: New sequencing service starts up in Israel – 11-12, 14

New sequencing kits from Roche accelerate further Cancer-/SNP Research and population genetics – 11-12, 15

ROZZELL J. D.

Expanded opportunities for biocatalysis – 5, 17

Ketoreductases: General stereoselective catalysts for the facile synthesis of a broad range of chiral alcohols – 9, 2

RYZHIKOV A. B.

The prospects of synthetic antigens in diagnostics and vaccinal prevention of highly genetically variable infectious agents – 11-12, 6

RYZHIKOV E. A.

The prospects of synthetic antigens in diagnostics and vaccinal prevention of highly genetically variable infectious agents – 11-12, 6

S

SABINSA Corp.

Selenium SeLECT – An ingredient of Sabinisa Corporation – in *Company Profiles*, 20

SAGELSDORFF P.

Determination of reactive compounds – 3, 12

SAHOO U.

A pharmaceutical perspective on India – 7-8, 24

SAKAI T.

Impact of heterodimers between G-protein-coupled receptors for peptides: New promising targets or burdensome issues in drug development? – 10, 22

SANNA D.

Spectroscopic studies of Cu (II) complexes with an insect kinin analog – 4, 10

SATAKE H.

Impact of heterodimers between G-protein-coupled receptors for peptides: New promising targets or burdensome issues in drug development? – 10, 22

SIFAVITOR S.p.A.

Manufacturer of pharmaceutical active ingredients – in *Company Profiles*, 21

SINGH J.

Development of reliable hydrogenation data using parallel processing – 11-12, 10

SOLVIAS AG

Solvias Ligand Contest 2006 with two winners – 5, 6
Cost effective chemistry that works – in *Company Profiles*, 22

SPADARO M.

Biotech patents: The Italian situation – 7-8, 2

SYKULA A.

Spectroscopic studies of Cu (II) complexes with an insect kinin analog – 4, 10

T

TAO JUNHUA

Applications of biocatalysis in the

development of green chemistry – 9, 34

TCI EUROPE N.V.

in *Company Profiles*, inside back cover

THALMANN M.

Microreactor technology and continuous processes in the fine chemical and pharmaceutical industries – 6, 14

TOPHARMAN

in *Company Profiles*, inside back cover

U

UBICHEM plc

Water soluble carbodiimide – 10, 16

V

VIDAL M.

Peptides as antagonists of the VEGF receptors – 4, 15

VINK M. K. S.

Expanded opportunities for biocatalysis – 5, 17

VORHERR T.

Peptides: Impact of new technologies on chemical production – 7-8, 14

VORWERK C.

cOMplete lysis kits: Rapid protein extraction and simultaneous protection against proteases – 9, 24

W

WALDRAM D.

Setting new drug specifications – An outsourcing API supplier's perspective – 3, 44

WARD R. J.

Metal-based neurodegeneration – 1-2, 37

WESTERHAUS A.

A new beginning – 1-2, 42
Saltigo is ready to go – 6, 38

WILLS M.

Weighing is optional: Highly active and practical catalysts for asymmetric ketone transfer hydrogenation – 9, 8

Z

ZABROCKI J.

Spectroscopic studies of Cu (II) complexes with an insect kinin analog – 4, 10

ZAMBON FINE CHEMICALS

Reliability, responsiveness and innovation – Interview to J.-F. MARCOPOULOS – 10, 40

ZHANG YANFENG

Synthesis and characterisation of new AB-PBO monomers and their application – 6, 30

Efficient synthesis and application of new AB-PBO monomers – 9, 30

ZHAO LISHAN

Applications of biocatalysis in the development of green chemistry – 9, 34